Oral administration of the nucleoside EFdA (4′-ethynyl-2-fluoro-2′-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4190-4198

  Stoddart, Cheryl A ^a   Galkina, Sofiya A ^a   Joshi, Pheroze ^a   Kosikova, Galina ^a   Moreno, Mary E ^a   Rivera, Jose M ^a   Sloan, Barbara ^a   Reeve, Aaron B ^b   Sarafianos, Stefan G ^c   Murphey Corb, Michael ^b   Parniak, Michael A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' ETHYNYL 2 FLUORO 2' DEOXYADENOSINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYADENOSINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; DIAZONIUM COMPOUND; EPOXYFARNESYL DIAZOACETATE; FARNESOL; VIRUS RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; ELIMINATION HALF-LIFE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC90; LOW DRUG DOSE; MACACA; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIREMIA; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; FLOW CYTOMETRY; HALF LIFE TIME; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MONOCYTE; RHESUS MONKEY; SCID MOUSE; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; BLOOD-BRAIN BARRIER; DIAZONIUM COMPOUNDS; FARNESOL; FLOW CYTOMETRY; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; IN VITRO TECHNIQUES; MACACA MULATTA; MICE; MICE, SCID; MONOCYTES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA;

EID: 84935846302     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05036-14     Document Type: Article

References (31)

1. Snedecor SJ, Sudharshan L, Nedrow K, Bhanegaonkar A, Simpson KN, Haider S, Chambers R, Craig C, Stephens J. 2014. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. AIDS Res Hum Retroviruses 30:753-768. http://dx.doi.org/10.1089/aid.2013.0262.
2. Ibe S, Sugiura W. 2011. Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations. Future Microbiol 6:295-315. http://dx.doi.org/10.2217/fmb.11.7.
3. Michailidis E, Marchand B, Kodama EN, Singh K, Matsuoka M, Kirby KA, Ryan EM, Sawani AM, Nagy E, Ashida N, Mitsuya H, Parniak MA, Sarafianos SG. 2009. Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem 284:35681-35691. http://dx.doi.org/10.1074/jbc.M109.036616.
4. Hattori S, Ide K, Nakata H, Harada H, Suzu S, Ashida N, Kohgo S, Hayakawa H, Mitsuya H, Okada S. 2009. Potent activity of a nucleoside reverse transcriptase inhibitor, 4′-ethynyl-2-fluoro-2′-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice. Antimicrob Agents Chemother 53:3887-3893. http://dx.doi.org/10.1128/AAC.00270-09.
5. Kawamoto A, Kodama E, Sarafianos SG, Sakagami Y, Kohgo S, Kitano K, Ashida N, Iwai Y, Hayakawa H, Nakata H, Mitsuya H, Arnold E, Matsuoka M. 2008. 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol 40:2410-2420. http://dx.doi.org/10.1016/j.biocel .2008.04.007.
6. Kohgo S, Yamada K, Kitano K, Sakata S, Hayakawa H, Nameki D, Kodama E, Matsuoka M, Mitsuya H, Ohrui H. 2003. Synthesis of 4′-C-ethynyl and 4′-C-cyano purine nucleosides from natural nucleosides and their anti-HIV activity. Nucleosides Nucleotides Nucleic Acids 22:887-889. http://dx.doi.org/10.1081/NCN-120022678.
7. Nakata H, Amano M, Koh Y, Kodama E, Yang G, Bailey CM, Kohgo S, Hayakawa H, Matsuoka M, Anderson KS, Cheng YC, Mitsuya H. 2007. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob Agents Chemother 51:2701-2708. http: //dx.doi.org/10.1128/AAC.00277-07.
8. Ohrui H, Kohgo S, Hayakawa H, Kodama E, Matsuoka M, Nakata T, Mitsuya H. 2007. 2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma. Nucleosides Nucleotides Nucleic Acids 26:1543-1546. http://dx.doi.org/10.1080/15257770701545218.
9. Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG. 2013. Effects of substitutions at the 4′ and 2 positions on the bioactivity of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob Agents Chemother 57:6254-6264. http: //dx.doi.org/10.1128/AAC.01703-13.
10. Michailidis E, Huber AD, Ryan EM, Ong YT, Leslie MD, Matzek KB, Singh K, Marchand B, Hagedorn AN, Kirby KA, Rohan LC, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG. 2014. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem 289:24533-24548. http://dx.doi.org/10.1074/jbc.M114.562694.
11. Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H. 2014. Delayed emergence of HIV-1 variants resistant to 4′-ethynyl-2-fluoro-2′deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antivir Ther 19:179-189. http://dx.doi.org/10.3851/IMP2697.
12. Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, Datema R, Charpiot B, Seifert J, Kaneshima H, McCune JM. 1996. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Antimicrob Agents Chemother 40:755-762.
13. Stoddart CA, Bales CA, Bare JC, Chkhenkeli G, Galkina SA, Kinkade AN, Moreno ME, Rivera JM, Ronquillo RE, Sloan B, Black PL. 2007. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. PLoS One 2:e655. http://dx.doi.org/10.1371/journal.pone.0000655.
14. Long BR, Stoddart CA. 2012. Alpha interferon and HIV infection cause activation of human T cells in NSG-BLT mice. J Virol 86:3327-3336. http: //dx.doi.org/10.1128/JVI.06676-11.
15. Covassin L, Jangalwe S, Jouvet N, Laning J, Burzenski L, Shultz LD, Brehm MA. 2013. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rgamma(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells. Clin Exp Immunol 174:372-388. http://dx.doi.org/10.1111/cei.12180.
16. Greenblatt MB, Vrbanac V, Tivey T, Tsang K, Tager AM, Aliprantis AO. 2012. Graft versus host disease in the bone marrow, liver and thymus humanized mouse model. PLoS One 7:e44664. http://dx.doi.org/10.1371 /journal.pone.0044664.
17. Cann AJ, Zack JA, Go AS, Arrigo SJ, Koyanagi Y, Green PL, Pang S, Chen IS. 1990. Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol 64:4735-4742.
18. Haltiner M, Kempe T, Tjian R. 1985. A novel strategy for constructing clustered point mutations. Nucleic Acids Res 13:1015-1025. http://dx.doi .org/10.1093/nar/13.3.1015.
19. Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen IS. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819-822. http://dx.doi.org/10.1126/science.3646751.
20. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
21. Brown BK, Darden JM, Tovanabutra S, Oblander T, Frost J, Sanders-Buell E, de Souza MS, Birx DL, McCutchan FE, Polonis VR. 2005. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J Virol 79:6089-6101. http://dx.doi.org/10.1128/JVI.79.10.6089-6101.2005.
22. Jagodzinski LL, Wiggins DL, McManis JL, Emery S, Overbaugh J, Robb M, Bodrug S, Michael NL. 2000. Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol 38:1247-1249.
23. Michael NL, Herman SA, Kwok S, Dreyer K, Wang J, Christopherson C, Spadoro JP, Young KK, Polonis V, McCutchan FE, Carr J, Mascola JR, Jagodzinski LL, Robb ML. 1999. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 37:2557-2563.
24. Vahey M, Nau ME, Barrick S, Cooley JD, Sawyer R, Sleeker AA, Vickerman P, Bloor S, Larder B, Michael NL, Wegner SA. 1999. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol 37:2533-2537.
25. Murphey-Corb M, Martin LN, Rangan SR, Baskin GB, Gormus BJ, Wolf RH, Andes WA, West M, Montelaro RC. 1986. Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 321:435-437. http: //dx.doi.org/10.1038/321435a0.
26. Baskin GB, Murphey-Corb M, Watson EA, Martin LN. 1988. Necropsy findings in rhesus monkeys experimentally infected with cultured simian immunodeficiency virus (SIV)/delta. Vet Pathol 25:456-467. http://dx.doi.org/10.1177/030098588802500609.
27. Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, Allaway GP, Wild CT, Martin DE. 2007. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One 2:e1251. http://dx.doi.org/10.1371/journal.pone.0001251.
28. Stoddart CA, Moreno ME, Linquist-Stepps VD, Bare C, Bogan MR, Gobbi A, Buckheit RW, Jr, Bedard J, Rando RF, McCune JM. 2000. Antiviral activity of 2′-deoxy-3′-oxa-4′-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrob Agents Chemother 44:783-786. http://dx.doi.org/10.1128/AAC.44.3.783-786.2000.
29. Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA. 2012. Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo. Antimicrob Agents Chemother 56:4707-4712. http://dx.doi.org/10.1128 /AAC.00723-12.
30. Gootz TD, Subashi TA, Lindner DL. 1988. Simple spectrophotometric assay for measuring protein binding of penem antibiotics in human serum. Antimicrob Agents Chemother 32:159-163. http://dx.doi.org/10 .1128/AAC.32.2.159.
31. Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, Swanson MD, Chateau M, Nochi T, Krisko JF, Spagnuolo RA, Margolis DM, Garcia JV. 2012. Generation of HIV latency in humanized BLT mice. J Virol 86:630-634. http://dx.doi.org/10.1128/JVI.06120-11.